Pharma

Taking stock of the drug industry, from the lab to the medicine chest

Overcoming Opioids Better Drugs
Pharmalot

Drug wholesalers sue New York over an opioid stewardship program

By Ed Silverman

Pharmalot

Novartis is the latest big drug maker to exit antibiotic research

By Ed Silverman

Seema Verma CAR-T
Politics

U.S. ended value-based pricing plan for cancer drug because of doubts it would work

By Ike Swetlitz

Pharmalot

Pharmalittle: Most drug price hikes occurred before Azar arrived; Novartis abandons antibiotics

By Ed Silverman

Trump + Read
Politics

What Pfizer, Trump, and consumers got out of a surprising deal — and what they didn’t

By Erin Mershon and Ike Swetlitz

Elijah Cummings 2017
Pharmalot

Cummings probes Trump administration official over potential conflicts with drug maker

By Ed Silverman

Pharmalot

Lawmaker wants to know if Trump and Pfizer cut any secret deals

By Ed Silverman

Pharmalot

Pharmalittle: California transparency law stalls some price hikes; Pfizer reorganizes operations, again

By Ed Silverman

Row Of Rabbits
In the Lab

Computers may surpass rabbits and rodents for some chemical safety tests

By Eric Boodman

Pharmalot
Pharmalot

Under pressure from Trump, Pfizer agrees to roll back price hikes

By Ed Silverman

FDA campus
Pharma

Could FDA use off-label data for drug approvals? It’s possible, agency official says

By Ike Swetlitz

Kim Kardashian
Pharmalot

A drug maker paid Kim Kardashian $500,000 for a few social media posts. Were they worth it?

By Ed Silverman

Opioid Lawyers
Pharmalot

A Russian court grants a compulsory license for a best-selling Celgene drug

By Ed Silverman

Pharmalot

Pharmalittle: Sanofi closes a plant over environmental concerns; Azar promises changes to 340B

By Ed Silverman

President Trump Delivers Remarks On Lowering Drug Prices In Rose Garden
The Pharmalot View

He can shame Pfizer and others, but Trump doesn’t have a practical way to lower drug prices

By Ed Silverman

Alex Azar - Senate Finance Committee hearing
Politics

Azar makes case for revamping hospital drug discounts — to hospitals defending them

By Erin Mershon

Pharmalot

Pharmalittle: CMS drops plan for Novartis drug; lawsuit offers fresh details on Purdue opioid marketing

By Ed Silverman

Vertex Pharmaceuticals Inc. building
Pharmalot

Vertex CEO complains to U.K. prime minister about stalled talks over a pricey drug

By Ed Silverman

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: FDA fails to police ‘pay-later’ conflicts; Philippines readies suit against Sanofi over dengue vaccine

By Ed Silverman

Tuberculosis Priority
Pharmalot

U.S. pushes back on global declaration for TB drugs, a move advocacy groups say will restrict access

By Ed Silverman

Vertex
Pharmalot

Vertex and U.K. health officials reach an impasse over pricey cystic fibrosis drug

By Ed Silverman

Pharma

Pharmalittle: CVS tells Azar it is not blocking lower drug prices; pharma sheds lots more jobs in the U.S.

By Ed Silverman

Pharmalot
Pharmalot

Teamsters urge McKesson shareholders to dump the audit committee chair over opioid crisis

By Ed Silverman

Pharmalot

Trump promised drug makers would lower their prices, but not every company got the memo

By Ed Silverman

Pharmalot

Pharmalittle: Cost of HIV prevention pill prevents adoption; senators ask PBMs to explain their role in drug pricing

By Ed Silverman

Pharma

Companies are racing to develop fast-acting depression drugs — but the process is tricky

By Megan Thielking

Mylan
Pharmalot

FDA reprimands Mylan for shoddy quality control at a key plant

By Ed Silverman

AbbVie California
Pharmalot

AbbVie and its partner ordered to pay $448 million over a pay-to-delay case

By Ed Silverman

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy